Anonymous: "Definition of cemiplimab-rwlc - NCI Drug Dictionary - National Cancer Institute", , 23 October 2018 (2018-10-23), XP055668903, Retrieved from the Internet: URL:https://web.archive.org/web/2018102315 4256/https://www.cancer.gov/publications/d ictionaries/cancer-drug/def/anti-pd-1-mono clonal-antibody-regn2810?redirect=true [retrieved on 2020-02-14] (B1)

Anonymous: "Intralesional Cemiplimab for Patients With Cutaneous Squamous Cell Carcinoma or Basal Cell Carcinoma - Full Text View - ClinicalTrials.gov", , 1 August 2022 (2022-08-01), XP055978236, Retrieved from the Internet: URL:https://clinicaltrials.gov/ct2/show/NC T03889912?term=cemiplimab&draw=2&rank=7 [retrieved on 2022-11-07] (B1)

WO-A1-2018/106862 (B1)

Michael R. Migden ET AL: "PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma", The New England journal of medicine, vol. 379, no. 4, 26 July 2018 (2018-07-26) , pages 341-351, XP055694330, US ISSN: 0028-4793, DOI: 10.1056/NEJMoa1805131 (B1)

US-A1- 2018 243 413 (B1)

LUUK VAN HOOREN ET AL: "Local checkpoint inhibition of CTLA-4 as a monotherapy or in combination with anti-PD1 prevents the growth of murine bladder cancer", EUROPEAN JOURNAL OF IMMUNOLOGY, vol. 47, no. 2, 1 February 2017 (2017-02-01), pages 385-393, XP055596696, Weinheim ISSN: 0014-2980, DOI: 10.1002/eji.201646583 (B1)